Nephritis - 6 News

Tip: You can further refine your news selection by organizations.

Nephritis - 6 News

Tip: You can further refine your news selection by organizations.

Merck Serono Enters into Research Agreement with Pfizer and Broad Institute

03-Apr-2014 - Merck Serono announced that its U.S. affiliate EMD Serono has signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The ...

nephritis autoimmune diseases biomarkers

CellCept reaches positive results in Phase III trial in Lupus Nephritis

07-Jun-2010 - Vifor Pharma, the pharma business sector of the Galenica Group, and Roche announced that the maintenance phase of the Aspreva Lupus Management Study (ALMS) has successfully achieved its primary endpoint. The trial demonstrates the superiority of Roche’s CellCept (mycophenolate mofetil) versus ...

nephritis cyclophosphamide medicine

New therapeutic approach identified for kidney disease associated with lupus

27-Jan-2010 - Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The study was led by investigators at Hospital for Special Surgery and appears in Proceedings of the National ...

nephritis dialysis growth factors

Genentech and Biogen Idec Announce Positive Results from a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis

30-Aug-2006 - Genentech, Inc. and Biogen Idec, Inc. announced that a Phase II study of Rituxan® (Rituximab) for relapsing-remitting multiple sclerosis (RRMS) met its primary endpoint. The study of 104 patients showed a statistically significant reduction in the total number of gadolinium enhancing T1 lesions ...

nephritis autoimmune diseases multiple sclerosis

FDA approves Rituxan as first targeted B-cell therapy for treatment of rheumatoid arthritis

02-Mar-2006 - Genentech, Inc. and Biogen Idec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan® (Rituximab) in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with ...

nephritis autoimmune diseases food

Lonza Biologics and Alexion Pharmaceuticals sign agreement for commercial manufacturing

07-Jan-2003 - Alexion Pharmaceuticals, Inc. announced the execution of a large scale product supply agreement with Lonza Biologics for the long term commercial manufacture of its C5 complement inhibitor antibody, eculizumab. Alexion recently announced promising clinical results from clinical studies evaluating ...

nephritis antibodies clinical trials
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,302 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now